Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 23

Publication Record

Connections

Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
Selitsky SR, Dinh TA, Toth CL, Kurtz CL, Honda M, Struck BR, Kaneko S, Vickers KC, Lemon SM, Sethupathy P
(2015) MBio 6: e01500-15
MeSH Terms: Carcinoma, Hepatocellular, Cholesterol, Gene Expression Profiling, Gene Expression Regulation, Genetic Markers, Hepatitis B, Chronic, Hepatitis C, Chronic, High-Throughput Nucleotide Sequencing, Humans, Liver, Liver Neoplasms, MicroRNAs
Show Abstract · Added April 25, 2016
UNLABELLED - Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated hepatocellular carcinoma (HCC) are characterized by cholesterol imbalance and dyslipidemia; however, the key regulatory drivers of these phenotypes are incompletely understood. Using gene expression microarrays and high-throughput sequencing of small RNAs, we performed integrative analysis of microRNA (miRNA) and gene expression in nonmalignant and matched cancer tissue samples from human subjects with CHB or CHC and HCC. We also carried out follow-up functional studies of specific miRNAs in a cell-based system. These studies led to four major findings. First, pathways affecting cholesterol homeostasis were among the most significantly overrepresented among genes dysregulated in chronic viral hepatitis and especially in tumor tissue. Second, for each disease state, specific miRNA signatures that included miRNAs not previously associated with chronic viral hepatitis, such as miR-1307 in CHC, were identified. Notably, a few miRNAs, including miR-27 and miR-224, were components of the miRNA signatures of all four disease states: CHB, CHC, CHB-associated HCC, and CHC-associated HCC. Third, using a statistical simulation method (miRHub) applied to the gene expression data, we identified candidate master miRNA regulators of pathways controlling cholesterol homeostasis in chronic viral hepatitis and HCC, including miR-21, miR-27, and miR-33. Last, we validated in human hepatoma cells that both miR-21 and miR-27 significantly repress cholesterol synthesis and that miR-27 does so in part through regulation of the gene that codes for the rate-limiting enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR).
IMPORTANCE - Hepatitis B virus (HBV) and hepatitis C virus (HCV) are phylogenetically unrelated hepatotropic viruses that persistently infect hundreds of millions of people world-wide, often leading to chronic liver disease and hepatocellular carcinoma (HCC). Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated HCC often lead to cholesterol imbalance and dyslipidemia. However, the regulatory mechanisms underlying the dysregulation of lipid pathways in these disease states are incompletely understood. MicroRNAs (miRNAs) have emerged as critical modulators of lipid homeostasis. Here we use a blend of genomic, molecular, and biochemical strategies to identify key miRNAs that drive the lipid phenotypes of chronic viral hepatitis and HCC. These findings provide a panoramic view of the miRNA landscape in chronic viral hepatitis, which could contribute to the development of novel and more-effective miRNA-based therapeutic strategies.
Copyright © 2015 Selitsky et al.
0 Communities
1 Members
0 Resources
12 MeSH Terms
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L
(2015) J Hepatol 63: 1103-10
MeSH Terms: Alleles, Antiviral Agents, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Interleukins, Male, Middle Aged, Polymorphism, Genetic, RNA, Viral
Show Abstract · Added August 15, 2017
BACKGROUND & AIMS - Genetic polymorphisms within the interferon lambda (IFN-λ) region are strongly associated with hepatitis C virus (HCV) clearance; the IFNL4-ΔG/TT (rs368234815) polymorphism, which controls the generation of IFN-λ4 protein, is more strongly associated with HCV clearance than rs12979860 (the 'IL28B variant'). An IFNL3 3' untranslated region polymorphism (rs4803217) has been proposed as a causal variant that may affect HCV clearance by altering IFNL3 mRNA stability.
METHODS - We compared IFNL4-ΔG/TT and rs4803217 for association with response to pegylated-IFN-α/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. Genotyping was performed with TaqMan assays. We compared differences in mean reduction in HCV RNA levels by genotype and haplotype. For HCV clearance, we calculated p-values comparing c-statistics for IFNL4-ΔG/TT and rs4803217 genotypes by a bootstrap approach.
RESULTS - Among European Americans, linkage disequilibrium between IFNL4-ΔG/TT and rs4803217 was strong (r(2)=0.89-0.99) and there were no significant differences between the variants. In African American (AA) individuals enrolled in VIRAHEP-C, HCV RNA at treatment day 28 was more strongly associated with IFNL4-ΔG/TT than rs4803217 (p=0.003); the IFNL4-ΔG:rs4803217-G haplotype, which includes the putatively favorable IFNL3 allele, was actually associated with the poorest day 28 response (p=0.03, comparison to IFNL4-ΔG:rs4803217-T haplotype). Among AA participants, associations were stronger for IFNL4-ΔG/TT than rs4803217 for undetectable HCV RNA at week 24 in Virahep-C (p=0.03) and week 20 in HALT-C (p=0.03), as well as for spontaneous HCV clearance (p=0.048).
CONCLUSION - IFNL4-ΔG/TT is the primary IFN-λ region polymorphism for impaired HCV clearance.
Published by Elsevier B.V.
0 Communities
1 Members
0 Resources
12 MeSH Terms
Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.
Sosa R, Gailani D, Neff AT
(2014) Haemophilia 20: e429-32
MeSH Terms: Adult, Antibodies, Antiviral Agents, Blood Coagulation Factor Inhibitors, Factor XIII, Factor XIII Deficiency, Female, Hepatitis C, Chronic, Humans, Immunosuppressive Agents, Treatment Outcome
Added January 20, 2015
0 Communities
1 Members
0 Resources
11 MeSH Terms
Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients.
Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H
(2013) J Gastroenterol 48: 366-73
MeSH Terms: Adolescent, Adult, Aged, Aged, 80 and over, Body Mass Index, Carcinoma, Hepatocellular, Female, Follow-Up Studies, Hepacivirus, Hepatitis C, Chronic, Humans, Hyperplasia, Liver Neoplasms, Lymph Nodes, Male, Middle Aged, Risk Factors, Sex Factors, Ultrasonography, Viral Load, Young Adult
Show Abstract · Added May 2, 2014
BACKGROUND - Perihepatic lymph node enlargement (PLNE) is a common ultrasound finding in chronic hepatitis C patients. Although PLNE is considered to reflect the inflammatory response to hepatitis C virus (HCV), its clinical significance remains unclear.
METHODS - Between December 2004 and June 2005, we enrolled 846 chronic hepatitis C patients in whom adequate ultrasound examinations had been performed. PLNE was defined as a perihepatic lymph node that was at least 1 cm in the longest axis by ultrasonography. We analyzed the clinical features of patients with PLNE and prospectively investigated the association between PLNE and hepatocellular carcinoma (HCC) development.
RESULTS - We detected PLNE in 169 (20.0%) patients. Female sex, lower body mass index (BMI), and HCV serotype 1 were independently associated with the presence of PLNE. However, there were no significant differences in liver function tests, liver stiffness, and hepatitis C viral loads between patients with and without PLNE. During the follow-up period (mean 4.8 years), HCC developed in 121 patients. Unexpectedly, patients with PLNE revealed a significantly lower risk of HCC development than those without PLNE (p = 0.019, log rank test). Multivariate analysis revealed that the presence of PLNE was an independent negative predictor of HCC development (hazard ratio 0.551, p = 0.042). In addition, the sustained viral response rate in patients who received interferon (IFN) therapy was significantly lower in patients with PLNE than in patients without PLNE.
CONCLUSIONS - Patients with PLNE had a lower risk of HCC development than those without PLNE. This study may provide new insights into daily clinical practice and the pathophysiology of HCV-induced hepatitis and hepatocarcinogenesis.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.
Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K
(2012) World J Gastroenterol 18: 1385-90
MeSH Terms: Aged, Disease Progression, Elasticity Imaging Techniques, Female, Hepatitis C, Chronic, Humans, Liver, Male, Middle Aged, Transfusion Reaction
Show Abstract · Added May 2, 2014
AIM - To evaluate the relationship between liver stiffness and duration of infection in blood transfusion-associated hepatitis C virus (HCV) patients with or without hepatocellular carcinoma (HCC).
METHODS - Between December 2006 and June 2008, a total of 524 transfusion-associated HCV-RNA positive patients with or without HCC were enrolled. Liver stiffness was obtained noninvasively by using Fibroscan (Echosens, Paris, France). The date of blood transfusion was obtained by interview. Duration of infection was derived from the interval between the date of blood transfusion and the date of liver stiffness measurement (LSM). Patients were stratified into four groups based on the duration of infection (17-29 years; 30-39 years; 40-49 years; and 50-70 years). The difference in liver stiffness between patients with and without HCC was assessed in each group. Multiple linear regression analysis was used to determine the factors associated with liver stiffness.
RESULTS - A total of 524 patients underwent LSM. Eight patients were excluded because of unsuccessful measurements. Thus 516 patients were included in the current analysis (225 with HCC and 291 without). The patients were 244 men and 272 women, with a mean age of 67.8 ± 9.5 years. The median liver stiffness was 14.3 kPa (25.8 in HCC group and 7.6 in non-HCC group). The patients who developed HCC in short duration of infection were male dominant, having lower platelet count, with a history of heavier alcohol consumption, showing higher liver stiffness, and receiving blood transfusion at an old age. Liver stiffness was positively correlated with duration of infection in patients without HCC (r = 0.132, P = 0.024) but not in patients with HCC (r = -0.103, P = 0.123). Liver stiffness was significantly higher in patients with HCC than in those without in each duration group (P < 0.0001). The factors significantly associated with high liver stiffness in multiple regression were age at blood transfusion (P < 0.0001), duration of infection (P = 0.0015), and heavy alcohol consumption (P = 0.043).
CONCLUSION - Although liver stiffness gradually increases over time, HCC develops in patients with high stiffness value regardless of the duration of infection.
0 Communities
1 Members
0 Resources
10 MeSH Terms
Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.
Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y
(2011) Cancer Epidemiol Biomarkers Prev 20: 2204-11
MeSH Terms: ADAM Proteins, ADAMTS13 Protein, Aged, Alanine Transaminase, Aspartate Aminotransferases, Biomarkers, Tumor, Blood Proteins, Carcinoma, Hepatocellular, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Hepacivirus, Hepatic Stellate Cells, Hepatitis B virus, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis
Show Abstract · Added May 2, 2014
BACKGROUND - Chronic liver injury evokes a wound healing response, promoting fibrosis and finally hepatocellular carcinoma (HCC), in which hepatic stellate cells play an important role. Although a blood marker of hepatic stellate cells is not known, those cells importantly contribute to the regulation of plasma a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity, a defect of which causes thrombotic thrombocytopenic purpura.
METHODS - Plasma ADAMTS13 was evaluated in chronic hepatitis B or C patients with or without HCC.
RESULTS - Plasma ADAMTS13 activity significantly correlated with serum aspartate aminotransferase and alanine aminotransferase, liver stiffness value, and aspartate aminotransferase-to-platelet ratio index, irrespective of the presence of HCC, suggesting that it may reflect hepatocellular damage and subsequent wound healing and fibrosis as a result of hepatic stellate cell action. During the three-year follow-up period for patients without HCC, it developed in 10 among 81 patients. Plasma ADAMTS13 activity was significantly higher in patients with HCC development than in those without and was a significant risk for HCC development by univariate and multivariate analyses. Furthermore, during the one-year follow-up period for patients with HCC treated with radiofrequency ablation, HCC recurred in 55 among 107 patients. Plasma ADAMTS13 activity or antigen level was significantly higher in patients with HCC recurrence than in those without and was retained as a significant risk for HCC recurrence by multivariate analysis.
CONCLUSIONS - Higher plasma ADAMTS13 activity and antigen level was a risk of HCC development in chronic liver disease.
IMPACT - Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.
©2011 AACR
0 Communities
1 Members
0 Resources
23 MeSH Terms
Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.
Shimada M, Yoshida S, Masuzaki R, Schuppan D
(2012) J Hepatol 56: 299-300
MeSH Terms: Antiviral Agents, Drug Synergism, Hepatitis C, Chronic, Humans, Interferon-alpha, Pilot Projects, Prospective Studies, Quinolines, Random Allocation, Ribavirin, Viral Load
Added May 2, 2014
0 Communities
1 Members
0 Resources
11 MeSH Terms
Autotaxin as a novel serum marker of liver fibrosis.
Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y
(2011) Clin Chim Acta 412: 1201-6
MeSH Terms: Aged, Area Under Curve, Biomarkers, Female, Hepatitis C, Chronic, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Multienzyme Complexes, Phosphodiesterase I, Phosphoric Diester Hydrolases, Pyrophosphatases, ROC Curve, Retrospective Studies
Show Abstract · Added May 2, 2014
BACKGROUND - The clinical significance of autotaxin (ATX), a key enzyme for the production of the bioactive lysophospholipid lysophosphatidic acid remains unknown. Serum ATX enzymatic activity reportedly increases in parallel with liver fibrosis and exhibits a gender difference.
METHODS - Serum ATX antigen level, measured easier than the activity, was evaluated as a marker of liver fibrosis in 2 cohorts of chronic liver disease caused by hepatitis C virus.
RESULTS - In the first cohort, serum ATX level correlated significantly with liver fibrosis stage and was the best parameter for prediction of cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.756 in male and 0.760 in female, when compared with serum hyaluronic acid and aminotransferase-to-platelet ratio index, an established marker of liver fibrosis. In another cohort, serum ATX level correlated significantly with liver stiffness, a novel reliable marker of liver fibrosis, being the second-best parameter in male (AUROC, 0.799) and in female (AUROC, 0.876) for prediction of significant fibrosis, and the best parameter in male (AUROC, 0.863) and the third-best parameter in female (AUROC, 0.872) for prediction of cirrhosis, both of which were judged by liver stiffness.
CONCLUSIONS - Serum ATX level may be a novel marker of liver fibrosis.
Copyright © 2011 Elsevier B.V. All rights reserved.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients.
Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K
(2011) Int J Cancer 129: 2226-35
MeSH Terms: Adiponectin, Aged, Carcinoma, Hepatocellular, Cohort Studies, Female, Hepatitis C, Chronic, Humans, Incidence, Interleukin-6, Liver Neoplasms, Male, Middle Aged, Protein Isoforms, Retrospective Studies, Risk Assessment, Risk Factors
Show Abstract · Added May 2, 2014
Obesity and metabolic syndrome are recognized risk factors for development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC). Dysregulation of adipokines, particularly the decreased secretion of adiponectin, appears to play a key role. To investigate the association between adiponectin and hepatocarcinogenesis, we conducted a large-scale retrospective cohort study. We enrolled 325 patients with CHC (146 men, 179 women; mean age 58.0 ± 10.3 years) whose serum samples were collected between January 1994 and December 2002. Subjects were divided into two groups according to their serum adiponectin levels. We evaluated the association between adiponectin level and the risk of subsequent HCC development using univariate and multivariate Cox proportional hazard regression. Because average serum adiponectin level was higher in females than males, each gender was analyzed separately. Patients with CHC had significantly higher adiponectin levels than healthy controls. During the follow-up period (mean: 9.0 years), HCC developed in 122 subjects. Unexpectedly, subjects with higher serum adiponectin levels had a higher incidence of HCC (males: p = 0.032; females: p = 0.01; log-rank test). Multivariate analysis revealed that a high serum adiponectin level was independently associated with HCC development (hazard ratio [HR] = 2.07; p = 0.031 in females and HR = 1.82; p = 0.05 in males). Isoform analysis revealed that middle- and low-molecular-weight isoforms contributed to the risk of HCC. In conclusion, Patients who had CHC with high serum adiponectin levels had a higher risk of liver cancer development. Adiponectin may thus be tumorigenic or indicate a liver disease state independently of other clinical parameters.
Copyright © 2011 UICC.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R, Yoshida H, Omata M
(2010) Oncology 78 Suppl 1: 17-23
MeSH Terms: Antiviral Agents, Carcinoma, Hepatocellular, Chronic Disease, Clinical Trials as Topic, Hepacivirus, Hepatitis C, Chronic, Humans, Interferons, Liver Cirrhosis, Liver Neoplasms, Prognosis, Risk Factors
Show Abstract · Added May 2, 2014
The efficacy of interferon therapy against hepatitis C virus (HCV) has much improved, showing a sustained virologic response rate of 40-50% even in the genotype 1b with a high viral load. Several cohort studies conducted in Japan in the 1990s unanimously concluded that the risk of hepatocellular carcinoma (HCC) development was reduced in patients who achieved a sustained virologic response or persistent normalization of alanine aminotransferase as compared to untreated patients. Recently, a large-scale randomized controlled trial, called the HALT-C study, showed no significant difference in the incidence of HCC between patients on maintenance interferon therapy and those without. The reason for the discrepant results in Japanese and USA studies needs further clarification, together with analysis of the difference in incidence rates of HCC among cirrhotic patients. There has also been progress in the treatment of HCC, and together with advances in diagnostics facilitating HCC detection at an early stage, tumor nodules can often be completely removed either by medical ablation or surgical resection. Nevertheless, recurrence of HCC after apparently curative treatment is extraordinarily frequent, since the remaining liver is still at a high risk of HCC. The prevention of the recurrence of HCC, or tertiary prevention, is currently one of the most challenging tasks in hepatology.
Copyright (c) 2010 S. Karger AG, Basel.
0 Communities
1 Members
0 Resources
12 MeSH Terms